BOUNDLESS BIO, INC.

Boundless Bio, Inc. (BOLD) is a very small-cap biotechnology company. With a market capitalisation around $33 million, it is typical of early-stage biopharma firms where value is closely tied to clinical and regulatory milestones. Investors should know this is a high-risk, high-uncertainty profile: successful trials or partnerships can materially increase value, while setbacks, funding shortfalls or regulatory delays can have the opposite effect. Financial runway, data readouts, licensing deals and strategic collaborations are common near-term catalysts. Liquidity may be limited and shares can be volatile; dilution through capital raises is a realistic possibility. This summary provides general information for educational purposes and is not personalised investment advice — anyone considering an investment should perform their own due diligence and consider their risk tolerance and investment horizon.